Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression

@article{citeulike:2805285, abstract = {Background In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.Study Design Meta-analysis/metaregression.Setting \& Population Randomized clinical trials (RCTs).Selection Criteria for Studies RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.Intervention ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.Outcomes Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).Results We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95\% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95\% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.Limitations Only published data are included.Conclusions The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy.}, author = {Catapano, Fausta and Chiodini, Paolo and Nicola, Luca D. and Minutolo, Roberto and Zamboli, Pasquale and Gallo, Ciro and Conte, Giuseppe }, citeulike-article-id = {2805285}, doi = {10.1053/j.ajkd.2008.03.008}, journal = {American Journal of Kidney Diseases}, keywords = {acei, arb, dual, gn}, posted-at = {2008-05-16 14:35:34}, priority = {2}, title = {Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression}, url = {http://dx.doi.org/10.1053/j.ajkd.2008.03.008}, volume = {In Press, Corrected Proof} }

TY - JOUR ID - citeulike:2805285 L3 - citeulike-article-id:2805285 TI - Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression JF - American Journal of Kidney Diseases VL - In Press, Corrected Proof N2 - Background In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.Study Design Meta-analysis/metaregression.Setting & Population Randomized clinical trials (RCTs).Selection Criteria for Studies RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.Intervention ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.Outcomes Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).Results We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.Limitations Only published data are included.Conclusions The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy. KW - acei KW - arb KW - dual KW - gn AU - Catapano, Fausta AU - Chiodini, Paolo AU - Nicola, Luca AU - Minutolo, Roberto AU - Zamboli, Pasquale AU - Gallo, Ciro AU - Conte, Giuseppe UR - http://dx.doi.org/10.1053/j.ajkd.2008.03.008 ER -